[18F]FAPI-42 PET/CT与[18F]FDG PET/CT在复发性或转移性胃肠道间质瘤成像中的比较
本研究回顾性纳入35例复发性或转移性胃肠道间质瘤(R/M GISTs)患者,均行[18F]FAPI-42 PET/CT与[18F]FDG PET/CT。共识别106个病灶,FAPI PET/CT对R/M GISTs的阳性检出率高于FDG(80.2% vs. 53.8%,P<0.001),尤其肝转移(87.5% vs. 33.3%,P<0.001)。FAPI摄取与FAP表达水平对应,且不受肿瘤大小、强化程度、基因突变类型及靶向治疗影响。
要点
- FAPI PET/CT对R/M GISTs阳性检出率80.2%,高于FDG的53.8%(P<0.001)。
- FAPI PET/CT肝转移检出率87.5%,高于FDG的33.3%(P<0.001)。
- FAPI摄取与FAP表达水平对应,独立于肿瘤大小、强化程度、基因突变及靶向治疗。
核心结论
- FAPI用于R/M GISTs成像可能优于FDG,尤其对肝转移。
- FAPI摄取可反映FAP表达水平,且与FDG相比不依赖肿瘤大小、强化程度、基因突变类型及靶向治疗。
研究设计与样本
- 回顾性研究,纳入35例经病理或随访药物治疗效果确诊的R/M GISTs患者,均行FAPI PET/CT和FDG PET/CT。
- 比较双示踪剂PET/CT在不同部位的检出率和肿瘤/本底SUVmax比值(SUVTBR)。
- 评估肿瘤大小、强化程度、基因突变类型及靶向治疗对两种示踪剂摄取的影响。
- 对切除病灶(n=3)行免疫组化染色验证组织FAP表达。
主要发现
- 35例患者共识别106个病灶,其中38/106(35.8%)为FAPI阳性/FDG阴性,由FAPI PET/CT额外检出,包括26个肝转移、10个腹膜转移、1个胃肠道复发和1个骨转移。
- FAPI PET/CT对R/M GISTs的阳性检出率为80.2%,高于FDG的53.8%(P<0.001)。
- 肝转移的FAPI PET/CT检出率为87.5%,高于FDG的33.3%(P<0.001)。
- 肝转移的SUVTBR在FAPI PET/CT为2.4(0.3至11.2),高于FDG的0.9(0.3至6.5)(P<0.001)。
- FDG阳性组肿瘤最长径高于FDG阴性组(P=0.005),而FAPI阳性组与FAPI阴性组间无差异;两种示踪剂阳性组与阴性组间强化程度均无差异。
关键数值与推荐
- FAPI PET/CT对R/M GISTs阳性检出率80.2% vs. FDG 53.8%(P<0.001)。
- FAPI PET/CT对肝转移检出率87.5% vs. FDG 33.3%(P<0.001)。
- 肝转移SUVTBR:FAPI 2.4(0.3至11.2) vs. FDG 0.9(0.3至6.5)(P<0.001)。
- FDG阳性组肿瘤最长径高于FDG阴性组(P=0.005);FAPI阳性组与FAPI阴性组间无差异。
- FDG的SUVTBR在不同基因突变间(P<0.001)及靶向治疗与未靶向治疗组间(P=0.001)差异显著;FAPI无此差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PET has been important for monitoring recurrence and metastasis of Gastrointestinal Stromal Tumors (GISTs) and the selection of therapeutic strategies. A significant portion of GISTs lesions show negative FDG uptake and therefore calls for more tumor-specific imaging biomarkers. This study compared the imaging performance of [18F]FAPI-42 PET/CT and [18F]FDG PET/CT in recurrent or metastatic gastrointestinal stromal tumors (R/M GISTs). METHODS: This study retrospectively included 35 patients with R/M GISTs who underwent both FAPI PET/CT and FDG PET/CT. The definite diagnosis was confirmed by pathology or follow-up drug treatment effects. The differences in detection rates and tumor-to-background SUVmax ratio (SUVTBR) of different locations between dual-tracer PET/CT were compared. Factors including tumor size, degree of enhancement, type of gene mutation, and targeted treatment potentially influencing the uptake of both tracers were assessed. The excised lesions (n = 3) underwent immunohistochemical staining to verify FAP expression in the tissue. RESULTS: A total of 106 lesions in 35 patients were identified, out of which 38/106 (35.8%) lesions (FAPI + /FDG -) were additionally detected by FAPI PET/CT as compared to that by FDG, including 26 liver metastases, ten peritoneal metastases, one gastrointestinal recurrence, and one bone metastasis. The positive detection rate of FAPI PET/CT for recurrent or metastatic GISTs was higher than that of FDG (80.2% vs. 53.8%, P< 0.001), especially in liver metastases (87.5% vs. 33.3%, P< 0.001). Moreover, the SUVTBR of liver metastases of GISTs in FAPI PET/CT was higher than that in FDG [2.4 (0.3 to 11.2) vs. 0.9 (0.3 to 6.5), P< 0.001]. The longest diameter of tumors in the FDG-positive group was higher than that of the FDG-negative group (P= 0.005); still, it did not differ between the FAPI-positive group and the FAPI-negative group. No difference in the degree of enhancement was observed between both tracers' positive and negative groups. Besides, the SUVTBR of FDG but not FAPI differed significantly among various gene mutations (P< 0.001) as well as the targeted therapy and no targeted therapy groups (P= 0.001). FAP was expressed in R/M GISTs, and the uptake of FAPI corresponded to the level of FAP expression. CONCLUSION: In conclusion, FAPI for imaging of R/M GISTs could be superior to FDG, specifically for liver metastases. The uptake of FAPI could reflect the level of FAP expression, and it was independent of tumor size, degree of enhancement, type of gene mutation, and targeted therapy as compared to FDG.
引用
- Wu C, Zhang X, Zeng Y, et al. [18F]FAPI-42 PET/CT versus [18F]FDG PET/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors. Eur J Nucl Med Mol Imaging. 2022. PMID: 36040490. doi:10.1007/s00259-022-05955-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。